Teva to continue marketing Oxycodone until end of 2007

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) today announced that it will continue to sell its generic version of OxyContin tablets, manufactured by Purdue Frederick Company, at least through the end of 2007.

In October 2006, Teva settled a patent dispute with the Purdue Frederick pertaining to Teva's generic version of OxyContin, under which it was agreed that Teva could market its generic version of oxycodone HCl extended-release tablets through March 2007, after both companies said in August that Teva's license would not be extended past the end of 2006. The latest agreement could mean that Teva will not be able to continue manufacturing its generic version of OxyContin beyond the end of this year.

Oxycodone sales totaled $2 billion in 2004.

Published by Globes [online], Israel business news - www.globes.co.il - on March 6, 2007